Heat2Move

One of our paramount achievements has been securing the proprietary technology and patents for AnalgesiX Blue® following Philips' initial clinical trial. Despite the trial’s success in demonstrating the device’s efficacy, Philips did not publish the results. We are rectifying this by preparing to publish the data in a peer-reviewed journal, providing a robust foundation for the device’s mechanism of action and effectiveness as part of our strategic product launch. In addition, we've successfully cultivated substantial support, with over 20 Key Opinion Leaders (KOLs) endorsing our product. This advocacy represents a collective vote of confidence from esteemed professionals in the field of pain management, demonstrating the demand and trust in our innovation. These steps underscore our proactive approach to leveraging existing clinical data and enhancing our market presence by ensuring the scientific community and potential customers are well-informed about the benefits and capabilities of AnalgesiX Blue®. This, combined with our strategic partnerships and growing interest from both patients and clinicians, sets a strong precedent for our company's dedication to transforming the management of chronic lower back pain.